Interpace Biosciences, Inc. Share Price Other OTC
Equities
IDXG
US46062X3035
Managed Healthcare
Sales 2022 | 31.84M 2.55B | Sales 2023 | 40.21M 3.22B | Capitalization | 4.69M 376M |
---|---|---|---|---|---|
Net income 2022 | -22M -1.76B | Net income 2023 | - 0 | EV / Sales 2022 | 0.49 x |
Net Debt 2022 | 11.26M 902M | Net Debt 2023 | 7.69M 616M | EV / Sales 2023 | 0.31 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
6.03
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.42% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Burnell
CEO | Chief Executive Officer | 62 | 30/11/20 |
Director of Finance/CFO | 32 | 31/05/19 | |
Nicole Massoll
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Vijay Aggarwal
BRD | Director/Board Member | 75 | 31/01/22 |
Joseph Keegan
BRD | Director/Board Member | 71 | 31/12/15 |
Stephen Sullivan
BRD | Director/Board Member | 77 | 31/08/04 |
1st Jan change | Capi. | |
---|---|---|
-15.06% | 5.53B | |
+0.60% | 1.26B |